Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Pompilio

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Davide Integlia
TH Open : Companion Journal to Thrombosis and Haemostasis|May 2, 2020
Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysisGiuseppe Pompilio, Davide Integlia, Joseph Raffetto, et al.
Phlebology|May 13, 2021
Systematic literature review and network Meta-analysis of sulodexide and other drugs in chronic venous diseaseGiuseppe Pompilio, Andrew Nicolaides, Stavros K Kakkos, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Alessandro Morabito, Diego L Cortinovis, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Cycling of tumor necrosis factor inhibitors <i>versus</i> switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysisAlberto Migliore, Giuseppe Pompilio, Davide Integlia, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 16, 2019
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritisAlberto Migliore, Davide Integlia, Giuseppe Pompilio, et al.
Global & Regional Health Technology Assessment|October 9, 2023
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in ItalyAlison Davie, Sory Traoré, Massimo Giovannitti, et al.
Global & Regional Health Technology Assessment|July 9, 2024
Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyDavide Petruzzelli, Marco Vignetti, Stefania Trasarti, et al.
Global & Regional Health Technology Assessment|February 5, 2026
Erratum in: Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyDavide Petruzzelli, Marco Vignetti, Stefania Trasarti, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Davide Integlia
TH Open : Companion Journal to Thrombosis and Haemostasis|May 2, 2020
Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysisGiuseppe Pompilio, Davide Integlia, Joseph Raffetto, et al.
Phlebology|May 13, 2021
Systematic literature review and network Meta-analysis of sulodexide and other drugs in chronic venous diseaseGiuseppe Pompilio, Andrew Nicolaides, Stavros K Kakkos, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Alessandro Morabito, Diego L Cortinovis, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Cycling of tumor necrosis factor inhibitors <i>versus</i> switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysisAlberto Migliore, Giuseppe Pompilio, Davide Integlia, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 16, 2019
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritisAlberto Migliore, Davide Integlia, Giuseppe Pompilio, et al.
Global & Regional Health Technology Assessment|October 9, 2023
Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in ItalyAlison Davie, Sory Traoré, Massimo Giovannitti, et al.
Global & Regional Health Technology Assessment|July 9, 2024
Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyDavide Petruzzelli, Marco Vignetti, Stefania Trasarti, et al.
Global & Regional Health Technology Assessment|February 5, 2026
Erratum in: Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyDavide Petruzzelli, Marco Vignetti, Stefania Trasarti, et al.
Pageof 1